{"id":2968,"date":"2018-04-27T12:40:00","date_gmt":"2018-04-27T12:40:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/"},"modified":"2018-04-27T12:40:00","modified_gmt":"2018-04-27T12:40:00","slug":"report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/","title":{"rendered":"Report from Annual general meeting of XVIVO Perfusion AB (publ)"},"content":{"rendered":"

The following resolutions were amongst those adopted at XVIVO Perfusion\u2019s Annual General Meeting held on April 27, 2018:<\/span><\/p>\n

\u2022 No dividend will be paid for the financial year 2017.<\/span><\/p>\n

\u2022 G\u00f6sta Johannesson, Erik von Schenk, Camilla \u00d6berg and Folke Nilsson were re-elected as members of the Board, Yvonne M\u00e5rtensson and Alan Raffensperger were elected as new members of the Board and G\u00f6sta Johannesson was elected Chairman of the Board, all in accordance with the proposal of the Election Committee.<\/span><\/p>\n

\u2022 Remuneration totaling SEK 1,035,000 shall be paid to members of the Board: SEK 205,000 to the Chairman of the Board, SEK 130,000 to each of the other members of the Board, SEK 40,000 to the Chairman of the Audit Committee, SEK 40,000 to the Chairman of the Remuneration Committee and SEK 25,000 to each of the other members of these committees.
<\/span><\/p>\n

\u2022 The proposed principles for remuneration and other terms and conditions of employment were approved for senior management.<\/span><\/p>\n

\u2022 The Board was authorized, for a period of time up until the next Annual General Meeting and on one or more occasions, to take a decision to issue a maximum of 2,619,000 new shares, corresponding to just below 10 percent of the total number of shares and votes in the company.<\/span><\/p>\n

\u2022 The proposed issuance of a total of 315,000 warrants in accordance with the proposed warrants program was approved. The warrants shall be offered to all employees of the XVIVO Perfusion-group employed May 1, 2018, as well as new employees with the date of employment no later than October 19, 2018, at a price corresponding to the market value at the time of issuance. Holders of the warrants may subscribe for shares during the period from May 4, 2020 up until May 29, 2020. One warrant entitles the holder to subscribe for one new share in the company. Upon full exercise of the warrants, the share capital will increase by SEK 8,190, corresponding to a dilution of approximately 1,2 percent of the total number of shares and votes in the company. <\/span><\/p>\n

\u2022 The Board was authorized, for a period of time up until the next Annual General Meeting and on one or more occasions, to take a decision to acquire<\/span> shares in <\/span>XVIVO Perfusion AB<\/span> so that after each acquisition the Company holds no more than 10 percent of all the shares in the Company<\/span>.<\/span><\/p>\n

April 27, 2018
<\/span>Gothenburg
XVIVO Perfusion AB (publ)
The Board of Directors<\/p>\n

\n

For further information please contact:<\/span><\/p>\n

G\u00f6sta Johannesson, Chairman of the Board, +46 8\u00a0614 00 20<\/span>
Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/span><\/p>\n

This information is information that Xvivo Perfusion AB (publ) is obliged to make public.\u00a0\u00a0The information was submitted for publication, through the agency of the contact person set out above, at 2:40 pm CET on April 27, 2018.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The following resolutions were amongst those adopted at XVIVO Perfusion\u2019s Annual General Meeting held on April 27, 2018: \u2022 No…<\/p>\n","protected":false},"template":"","class_list":["post-2968","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-gm","mfn-news-tag-mfn-ci-gm-info"],"acf":[],"yoast_head":"\nReport from Annual general meeting of XVIVO Perfusion AB (publ) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Report from Annual general meeting of XVIVO Perfusion AB (publ) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"The following resolutions were amongst those adopted at XVIVO Perfusion\u2019s Annual General Meeting held on April 27, 2018: \u2022 No...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\\\/\",\"name\":\"Report from Annual general meeting of XVIVO Perfusion AB (publ) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2018-04-27T12:40:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Report from Annual general meeting of XVIVO Perfusion AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Report from Annual general meeting of XVIVO Perfusion AB (publ) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/","og_locale":"en_US","og_type":"article","og_title":"Report from Annual general meeting of XVIVO Perfusion AB (publ) - XVIVO","og_description":"The following resolutions were amongst those adopted at XVIVO Perfusion\u2019s Annual General Meeting held on April 27, 2018: \u2022 No...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/","name":"Report from Annual general meeting of XVIVO Perfusion AB (publ) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2018-04-27T12:40:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Report from Annual general meeting of XVIVO Perfusion AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}